ARCH Venture Partners (San Francisco, CA)
Ken Bradley, Ph.D., joined ARCH in January 2008 as Venture Partner in Chicago. Dr. Bradley has a rich background in discovering and developing nascent technologies and is supporting ARCH's life and physical sciences teams with a special focus on micro- and nanotechnologies.
Dr. Bradley most recently served as CEO of Arryx, a start-up company commercializing Holographic Optical Trapping technology for laser-based micro- and nano-scopic instrumentation in the life sciences sector. Arryx was acquired in 2007 by Haemonetics, a $2 billion firm headquartered in Massachusetts and developing blood management technologies that are key components of collection, surgery and transfusion services. Dr. Bradley continues to serve as Vice President of Development for Haemonetics.
Previously, Dr. Bradley founded and served as President of Phoenician Market Places, Inc., a technology innovation consultancy that fostered start-up companies by connecting laboratory advances with market opportunities. The consultancy's specialization included technology developed in academic and government research facilities and in early-stage commercial environments where there is large uncertainty in choosing optimum development paths.
Dr. Bradley began his career as an associate of Schlumberger-Doll Research and as a NATO Traveling Scholar. Dr. Bradley was an early member of the scientific staff at Nanophase Technologies, a nano-materials firm and an ARCH Venture Fund I and II portfolio company. He also held business development and general management roles in financial and data publishing.
Dr. Bradley received his post-doctoral training at MIT. He holds a Ph.D. in Experimental Condensed Matter Physics from Brown University and a B.A. in Physics from Cornell University.